What Is Claimed Is:

1. Use of (*S*)-bupropion that is at least 95% enantiomerically pure in the manufacture of a medicament for treating a neurological disorder or a central nervous system disorder in a human being, wherein the medicament is to be orally administered in a dosage form one or two times per day to the human being, wherein the dosage form includes 80 mg to 120 mg of the (S)-bupropion, and wherein the dosage form is more effective than administration of a dosage form including the same amount of (R)-bupropion in treating the same condition in the human being.

2. A kit comprising a dosage form and a label, wherein the dosage form comprises (*S*)-bupropion that is at least 95% enantiomerically pure, and the label states that the dosage form is to be orally administered one or two times per day to a human being for treating a condition in the human being, wherein the dosage form includes 80 mg to 120 mg of the (S)-bupropion, and wherein the dosage form is more effective than administration of a dosage form including the same amount of (R)-bupropion in treating the same condition in the human being.

3. The kit of claim 2, wherein the condition is a neurological disorder or a central nervous system disorder.

4. The kit of claim 3, wherein the human being is selected for having the condition.

5. The use of claim 1, or the kit of any one of claims 2-4, wherein the (*S*)-bupropion is to be administered once daily.

6. The use of claim 1, or the kit of any one of claims 2-4, wherein the (*S*)-bupropion is to be administered in two doses per day, and wherein the sum of the two doses per day is a daily dose.

7. The use of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 8 consecutive days.

8. The use of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 14 consecutive days.

9. The use of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 21 consecutive days.

10. The use of any one of claims 1, 5, or 6, or the kit of any one of claims 2-6, wherein the (*S*)-bupropion is to be administered for at least 28 consecutive days.

11. The use of any one of claims 1 or 5-10, or the kit of any one of claims 2-10, wherein the dosage form provides sustained release of the (*S*)-bupropion.

12. The use of claim 11, or the kit of claim 11, wherein the dosage form is formulated to have a T_{max} of (*S*)-bupropion that is 2 hours to 4 hours.

13. The use of any one of claims 1 or 5-12, or the kit of any one of claims 2-12, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is at least about 300 ng·hr/mL.

14. The use of any one of claims 1 or 5-12, or the kit of any one of claims 2-12, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is at least about 400 ng·hr/mL.

15. The use of any one of claims 1 or 5-14, or the kit of any one of claims 2-14, wherein the dosage form provides an AUC_{0-12} of (*S*)-bupropion in the human being that is 500 ng·hr/mL to 900 ng·hr/mL.

16. The use of any one of claims 1 or 5-15, or the kit of any one of claims 2-15, wherein the dosage form provides a C_{max} of (*S*)-bupropion in the human being that is 60 ng/mL to 140 ng/mL.

17. The use of any one of claims 1 or 5-15, or the kit of any one of claims 2-15, wherein the dosage form is substantially free of any active pharmaceutical ingredients other than (S)-bupropion.